Solutions
Three focused services for distinct early oncology development decisions.
Each service is built around a concrete buyer question: who it is for, what we analyze, what the client receives, and how the work moves forward.
01FIH Site & PI Matching
Prestige-heavy feasibility can miss overloaded investigators, slow activation patterns, patient competition, and weak mechanism fit.
For oncology sponsors moving from IND/CTA preparation toward first-patient-in.
Mechanism-specific site history, PI workload, matched trial experience, public recruitment signals, country mix, and regional risk.
A diligence-ready site / PI priority list, risk questions, and site mix recommendations for CRO and leadership discussions.
02Competitive Intelligence & Clinical Positioning
Peer movement can shape enrollment competition, country choices, endpoint expectations, differentiation, and partnering discussions.
For teams supporting clinical design, BD discussions, financing materials, or internal portfolio decisions.
Peer trial footprints, sponsor patterns, mechanism-specific design choices, endpoints, regional concentration, and public conference signals.
A focused report connecting external movement to clinical strategy, site planning, and BD narrative.
03China-to-Global Strategy
A local-only development logic can create later questions around regulatory communication, trial representativeness, country mix, and global partnering.
For Chinese oncology biotech companies planning US/global development, financing, or cross-border BD.
China evidence foundations, global competitor context, MRCT options, FDA-readiness questions, country pathways, site mix, and evidence-bridging risk.
A China-to-global development recommendation package connecting asset positioning, clinical evidence, and executable trial pathways.